Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAUTEM-T1: Neoadjuvant CRT + TEM vs TEM in T1 Rectal Cancer
NCT06450574Phase 3Not yet recruiting
- Sponsor
- Hospital Universitari Parc Taulí
- Start
- Oct 2024
- Primary completion
- Oct 2026
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
01
Overview
A Phase 3 trial of capecitabine in rectal cancer, sponsored by Hospital Universitari Parc Taulí. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
capecitabine
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT06450574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06450574.